Choose a folder
Spotlight on local publications: Turkey
Turkish investigators Dr Ferit Kerim Küçükler and Dr Mehmet Calan worked together with Dr Fahri Bayram, DISCOVER national coordinating investigator in Turkey, to develop and deliver two very successful oral presentations at local congresses.
Dr Mehmet Calan from Izmir Bozyaka Training and Research Hospital won third prize in the oral presentation category with his presentation titled First- and second-line treatment patterns and reasons for changing treatment in 536 patients with type 2 diabetes in Turkey: results from the global DISCOVER study (title translated from Turkish) at the National Diabetes Congress on 21 April in Antalya, Turkey. The data from 18 sites across Turkey showed that these patients initiated second-line treatment at a higher glycated haemoglobin (HbA1c) level than DISCOVER patients in Europe or the global DISCOVER population (7.1% vs 6.5% and 5.6%, respectively). The majority of Turkish DISCOVER patients used metformin as monotherapy (48.3%) or combined with a sulphonylurea (22.8%) as first-line treatment. Insulin (on its own or as part of a combination) was the most common second-line therapy and was much more frequently used than in the global DISCOVER population (32.1% versus 7.7% of patients); the second most common second-line therapy was metformin plus a dipeptidyl peptidase-4 inhibitor (20.3%). The main reason for switching from the first-line treatment was lack of efficacy (90.9%), and the main reason for choosing the second-line treatment was expected efficacy (75.9%). Overall, the study highlighted striking differences in treatment patterns and treatment inertia between Turkish patients and the overall DISCOVER population.
Dr Ferit Kerim Küçükler from Hitit University gave an oral presentation titled Multiple cardiovascular risk factor management according to guidelines in patients initiating second-line glucose-lowering treatment in Turkey: results from the global DISCOVER study (title translated from Turkish) at the Endocrinology and Metabolic Diseases Congress of Turkey on 11 May in Antalya, Turkey. The analysis included data from 536 Turkish patients at baseline (initiation of second-line treatment). As expected in patients initiating a second-line glucose-lowering therapy, only 11.7% of DISCOVER patients in Turkey had a HbA1c level below 7.0% (17.6% for the global DISCOVER population); the proportion of patients with HbA1c > 9.0% was higher in Turkey than in the overall DISCOVER population (40.6% versus 27.5%). The proportion of patients with a systolic blood pressure below the recommended target of 140 mmHg was similar in the Turkish patients and in the global DISCOVER population (62.5% and 67.7%, respectively). Additionally, 21.2% of Turkish DISCOVER patients had a low-density lipoprotein cholesterol (LDL-C) level below 100 mg/dL, the recommended target (43.5% for the global DISCOVER population). These results suggest a need for more proactive glycaemic and cardiovascular risk factor control for people with type 2 diabetes in Turkey.
Please continue to submit new proposals for future local and global analyses via the DISCOVER publications portal, and let us know if you would like to share the news of your presentations with the DISCOVER community.